Metabolism of Licofelone (ML3000): an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Abschlussarbeit Buch |
| Sprache: | English |
| Veröffentlicht: |
2007
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | VI, 184 S. graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV022506165 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 070711s2007 d||| m||| 00||| eng d | ||
| 035 | |a (OCoLC)254333337 | ||
| 035 | |a (DE-599)BSZ263945944 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29T |a DE-188 | ||
| 084 | |a 15,3 |2 ssgn | ||
| 100 | 1 | |a Unger, Anke |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Metabolism of Licofelone (ML3000) |b an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat |c von Anke Unger |
| 246 | 1 | 1 | |a Metabolismus von Licofelone (ML3000) |
| 264 | 1 | |c 2007 | |
| 300 | |a VI, 184 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 502 | |a Tübingen, Univ., Diss., 2007 | ||
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015713153&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015713153 | ||
Datensatz im Suchindex
| _version_ | 1804136607028084737 |
|---|---|
| adam_text | METABOLISM OF LICOFELONE (ML3000) - AN ANTI-INFLAMMATORY PYRROLIZINE
ACETIC ACID DERIVATIVE METABOLISMUS VON LICOFELONE (ML3000) - EIN
ENTZIINDUNGSHEMMENDES PYRROLIZINESSIGSAURE-DERIVAT DISSERTATION DER
FAKULTIIT FUR CHEMIE UND PHARMAZIC DCR EBERHARD-KARLS-L NIVERSITAT
TUBINGEN ZUR ERLANGUNG DES GRADES EINES DOKIORS DER N ATURWISSENSCHAFTEN
2007 VORGELEGT VON ANKE LNFZER TABLE OF CONTENTS 1 INTRODUCTION 1 2 IN
VITRO METABOLISM OF LICOFELONE 5 2.1 BACKGROUND AND OBJECTIVES 5 2.2
MATERIALS AND METHODS 11 2.2.1 TEST ARTICLES AND REFERENCE COMPOUNDS 11
2.2.2 CHEMICALS 13 2.2.3 APPARATUS 14 2.2.4 INSTRUMENTS 15 2.2.5
PREPARATION OF BUFFERS AND REAGENTS 16 2.2.6 MICROSOMAL PREPARATIONS,
PLASMA AND TISSUE 18 2.2.7 PRELIMINARY IN VITRO METABOLISM EXPERIMENTS
21 2.2.7.1 PHASE-1 METABOLISM ASSAYS 21 2.2.7.2 GLUCURONIDATION
EXPERIMENTS 22 2.2.7.3 SAMPLE PREPARATION ANDLC-MS/MS ANALYSIS 23 2.2.8
DETERMINATION OF ML3000-M4 IN PLASMA 24 2.2.X. 1 SAMPLE SELECTION 24
2.2.8.2 SAMPLE PREPARATION AND LC-MS/MS ANALYSIS 25 2.2.9 KINETIC
ANALYSIS OF IN VITRO GLUCURONIDATIONS 26 2.2.9.1 IN VITRO
GLUCURONIDATION ASSAVS 26 2 2.9 2 INTERACTION ASSAYS WITH ML3000.
ML3000-M2 AND ML3000-M4 2H 2.2.9.3 ANALYTICAL METHODS 29 2.2.10
BIOTRANSFORMATION OF ML3000. ML3247 AND DICLOFENAC IN PRIMARY HUMAN
HEPATOCYTES 31 2.2.10.1 CELL BIOLOGICAL PART 31 2.2.10.2 ANALYTICAL PART
32 2 2.11 DUAL ACTIVITY AND PHASE-I METABOLISM ASSAYS WITH ML3000.
ML3247 AND DICLOFENAC U ^ 2 I I.I INCUBATION EXPERIMENTS 34 - 112
LC-MS MS-ANALYSIS OF INCUBATION EXPERIMENTS WITH ML3000 AND ML3247 36 -
-11.3 HPLC II A NALYSIS OF IM LIBATION EXPERIMENTS WITH DICLOFENAC 39
*-*2.12 PHASE-1 METABOLISM ASSAYS WITH ML3000-M1 40 - 2.13
IDENTIFICATION OF CYTOCHROME P450 ISOFORMS 40 -*2.13.1 EXPERIMENTS WITH
ML3000 40 * ** EXPERIMENTS WITH ML3000-MI 4/ 2-2.14 IDENTIFICATION OF
LOT ISOFORMS 41 2.2.15 INHIBITION OFCYP2C8 BY ML3000-M1 41 2.2.16
INFLUENCE OF MONTELUKAST ON THE BIOTRANSFORMATION OF ML3000, ML3247 AND
DICLOFENAC 42 2.2.17 DETERMINATION OF ENANTIOMER RATIOS 42 2.2.17.1 IN
VITRO METABOLISM EXPERIMENTS 42 2.2.17.2 ANALYSIS OF HUMAN PLASMA
SAMPLES 43 2.2.17.3 HPLC/FLD ANALYSIS 44 2.2.18 VALIDATION OF THE
ANALYTICAL METHODS 45 152.IS.I ANALYSIS OF CALIBRATION STANDARDS 45
2.2.18.2 SPECIFICITY OF THE ANALYTICAL METHODS 46 2.2.18.3 ANALYTICAL
QUALITY CONTROL 46 2.2.18.4 INTERNAL STANDARDS 47 2.2.18.5 GLUCURONIDE
CONVERSION COEFFICIENT 48 2.2.19 DATA ANALYSIS 49 2.3 RESULTS 51 2.3.1
PRELIMINARY PHASE-I EXPERIMENTS 51 2.3.2 PRELIMINARY GLUCURONIDATION
EXPERIMENTS 55 2.3.3 REANALYSIS OF PLASMA SAMPLES FOR DETERMINATION OF
ML3000-M4 56 2.3.4 KINETICS OF IN VITRO GLUCURONIDATION 57 2.3.4.1
DETERMINATION OF K M , V^,, ANDCL IM * 57 2.3.4.2 INFLUENCE OF ML3000 ON
THE GLUCURONIDATION OF ML3000-M2 61 2.3.5 BIOTRANSFORMATION IN PRIMARY
HUMAN HEPATOCYTES 64 2.3.5.1 BIOTRANSFORMATION OF ML3000 64 2.3.5.2
BIOTRANSFORMATION OF ML3247 67 2.3.5.3 BIOTRANSFORMATION OF DICLOFENAC
68 2.3.6 COUPLED OXIDATIVE-CONJUGATIVE METABOLISM IN DIFFERENT
MICROSOMES 71 2.3.6.1 IN VITRO METABOLISM OF ML3000 72 2.3.6.2 IN VITRO
METABOLISM OF ML3247 *- 2.3.6.3 IN VITRO METABOLISM OF DICLOFENAC ^
2.3.7 IDENTIFICATION OF ENZYMES INVOLVED IN THE METABOLISM OF ML3000 89
2.3.7.1 IDENTIFICATION OF CYTOEHROME P450 ISOFORMS 90 2.3.7.2
IDENTIFICATION OF UDP- GLNCURONOSVLTRANSFERASE ISOFORMS 2.3.7.3
IDENTIFICATION OF CYTOEHROME P450 ISOFORMS INVOLVED IN THE OXIDATION OF
ML3000-M1 92 2.3.8 INHIBITION OF THE SEQUENTIAL OXIDATIVE METABOLISM -
2.3.8.1 INFLUENCE OF MONTELUKAST ON ML3000 AND ML3247 METABOLISM 92
2.3.8.2 IMPACT OF ML3000-MI ON CYP2C8-ACTIVITY 94 2.3.8.3 INFLUENCE OF
MONTELUKAST ON DICLOFENAC METABOLISM 95 2.3.9 DETERMINATION OF ML3OOO-M2
ENANTIOMER RATIOS 97 2.4 DISCUSSION 10 3 PHARMACOKINETICS AND
DISPOSITION OF LICOFELONE-PRODRUGS 111 3.1 BACKGROUND AND OBJECTIVES ILL
3.2 MATERIALS AND METHODS 115 3.2.1 TEST ARTICLES AND REFERENCE
COMPOUNDS 115 3.2.2 CHEMICALS 116 3.2.3 APPARATUS 117 3.2.4 INSTRUMENTS
118 3.2.5 PREPARATION OF BUFFERS AND REAGENTS 118 3.2.6 PHARMACOKINETICS
OF ML3599, ML3600, AND ML3601 IN DOGS 120 3.2.6.1 ALLOCATION OF ANIMALS
120 3.2.6.2 BLOOD SAMPLING AND PREPARATION OF PLASMA SAMPLES 120 3.2.6.3
DETERMINATION OFMLSOOO, ML3599, ML3600 ANA ML3601 BY LC-MS/MS AFTER
LIQUID-LIQUID EXTRACTION 121 3.2.7 INVESTIGATION OF TINE IN VITRO
STABILITY OF ML3599 AND ML3600 124 3.2.7.1 IN VITRO INCUBATIONS 124
3.2.7.2 ANALYSIS OF INCUBATION SAMPLES 125 3.2.8 PHARMACOKINETICS OF
CSY3100 AND CSY3104 IN RODENTS 126 3.2.8.1 ALLOCATION OF ANIMALS AND
SAMPLING 126 3.2.8.2 DETERMINATION OFCSY3100. CSY3104 AND ML3000 WITH
LC-MS/MS AFTER LIQUID-LIQUID EXTRACTION 127 3.2.9 IN VITRO METABOLISM OF
CSY3100 AND CSY3104 129 3.2.9.1 IN VITRO METABOLISM EXPERIMENTS 129
3.2.9.2 HPLC UV ANALYSIS OF IN VITRO METABOLISM SAMPLES 130 3.2.10
VALIDATION OF THE ANALYTICAL METHODS 130 3.2.10.1 ANALYSIS OF
CALIBRATION STANDARDS 130 3.2 10.2 SPECIFICITY OF THE ANALYTICAL METHODS
131 3.2.10.3 ANALYTICAL QUALITY CONTROL 131 3.2.10.4 INTERNAL STANDARDS
132 3.2.11 DATA ANALYSIS 132 3.3 RESULTS 133 3 3 1 PHARMACOKINETICS OF
ML3599. ML360OAND ML3601 IN DOGS 133 3.3.2 STABILITY OF ML3599 AND
ML36OO M VITRO 137 3.3.3 PHARMACOKINETICS OF ML3000 MACROLIDC CONJUGATES
13S 3 3.3.1 TREATMENT OF COLLAGEN-INDUCED ARTHRITIS IN MITE WITH CSY3KKI
AND CSY3I04 IN COMPARISON WITH ML.3000 138 3.3.3.2 SUB-ACUTE TOXICITY
OFCSY.I 100 AND CSY3104 IN MUE 139 3.3.3.3 PHARMACOKINETICS OF CSY3I0O
AND CSY3IO4 IN RATS 139 3.3.4 METABOLISM OF CSY3100 AND CSY3104 143 3.4
DISCUSSION 146 4 SUMMARY 149 5 ZUSAMMENFASSUNG 151 6 REFERENCES 153 7
ADDENDUM 165 7.1 CALIBRATION DATA 165 7.2 TABULATED RESULTS OF QC SAMPLE
ANALYSIS 166 7.3 RESULTS OF THE PLASMA ANALYSIS OF ML3000-M4 168 7.4
LINEWEAVER-BURK PLOTS OF GLUCURONIDATION EXPERIMENTS 171 7.5 TABULATED
RESULTS OF IN VITRO METABOLISM EXPERIMENTS 175 7.6 CHROMATOGRAMS AND
TABULATED RESULTS OF THE DETERMINATION OF ENANTIOMER RATIOS 181
|
| adam_txt |
METABOLISM OF LICOFELONE (ML3000) - AN ANTI-INFLAMMATORY PYRROLIZINE
ACETIC ACID DERIVATIVE METABOLISMUS VON LICOFELONE (ML3000) - EIN
ENTZIINDUNGSHEMMENDES PYRROLIZINESSIGSAURE-DERIVAT DISSERTATION DER
FAKULTIIT FUR CHEMIE UND PHARMAZIC DCR EBERHARD-KARLS-L'NIVERSITAT
TUBINGEN ZUR ERLANGUNG DES GRADES EINES DOKIORS DER N'ATURWISSENSCHAFTEN
2007 VORGELEGT VON ANKE LNFZER TABLE OF CONTENTS 1 INTRODUCTION 1 2 IN
VITRO METABOLISM OF LICOFELONE 5 2.1 BACKGROUND AND OBJECTIVES 5 2.2
MATERIALS AND METHODS 11 2.2.1 TEST ARTICLES AND REFERENCE COMPOUNDS 11
2.2.2 CHEMICALS 13 2.2.3 APPARATUS 14 2.2.4 INSTRUMENTS 15 2.2.5
PREPARATION OF BUFFERS AND REAGENTS 16 2.2.6 MICROSOMAL PREPARATIONS,
PLASMA AND TISSUE 18 2.2.7 PRELIMINARY IN VITRO METABOLISM EXPERIMENTS
21 2.2.7.1 PHASE-1 METABOLISM ASSAYS 21 2.2.7.2 GLUCURONIDATION
EXPERIMENTS 22 2.2.7.3 SAMPLE PREPARATION ANDLC-MS/MS ANALYSIS 23 2.2.8
DETERMINATION OF ML3000-M4 IN PLASMA 24 2.2.X. 1 SAMPLE SELECTION 24
2.2.8.2 SAMPLE PREPARATION AND LC-MS/MS ANALYSIS 25 2.2.9 KINETIC
ANALYSIS OF IN VITRO GLUCURONIDATIONS 26 2.2.9.1 IN VITRO
GLUCURONIDATION ASSAVS 26 2 2.9 2 INTERACTION ASSAYS WITH ML3000.
ML3000-M2 AND ML3000-M4 2H 2.2.9.3 ANALYTICAL METHODS 29 2.2.10
BIOTRANSFORMATION OF ML3000. ML3247 AND DICLOFENAC IN PRIMARY HUMAN
HEPATOCYTES 31 2.2.10.1 CELL BIOLOGICAL PART 31 2.2.10.2 ANALYTICAL PART
32 2 2.11 DUAL ACTIVITY AND PHASE-I METABOLISM ASSAYS WITH ML3000.
ML3247 AND DICLOFENAC "U ^ 2 I I.I INCUBATION EXPERIMENTS 34 ' - 112
LC-MS'MS-ANALYSIS OF INCUBATION EXPERIMENTS WITH ML3000 AND ML3247 36 -
-11.3 HPLC II' A NALYSIS OF IM LIBATION EXPERIMENTS WITH DICLOFENAC 39
*-*2.12 PHASE-1 METABOLISM ASSAYS WITH ML3000-M1 40 - 2.13
IDENTIFICATION OF CYTOCHROME P450 ISOFORMS 40 -*2.13.1 EXPERIMENTS WITH
ML3000 40 *"**' EXPERIMENTS WITH ML3000-MI 4/ 2-2.14 IDENTIFICATION OF
LOT ISOFORMS 41 2.2.15 INHIBITION OFCYP2C8 BY ML3000-M1 41 2.2.16
INFLUENCE OF MONTELUKAST ON THE BIOTRANSFORMATION OF ML3000, ML3247 AND
DICLOFENAC 42 2.2.17 DETERMINATION OF ENANTIOMER RATIOS 42 2.2.17.1 IN
VITRO METABOLISM EXPERIMENTS 42 2.2.17.2 ANALYSIS OF HUMAN PLASMA
SAMPLES 43 2.2.17.3 HPLC/FLD ANALYSIS 44 2.2.18 VALIDATION OF THE
ANALYTICAL METHODS 45 152.IS.I ANALYSIS OF CALIBRATION STANDARDS 45
2.2.18.2 SPECIFICITY OF THE ANALYTICAL METHODS 46 2.2.18.3 ANALYTICAL
QUALITY CONTROL 46 2.2.18.4 INTERNAL STANDARDS 47 2.2.18.5 GLUCURONIDE
CONVERSION COEFFICIENT 48 2.2.19 DATA ANALYSIS 49 2.3 RESULTS 51 2.3.1
PRELIMINARY PHASE-I EXPERIMENTS 51 2.3.2 PRELIMINARY GLUCURONIDATION
EXPERIMENTS 55 2.3.3 REANALYSIS OF PLASMA SAMPLES FOR DETERMINATION OF
ML3000-M4 56 2.3.4 KINETICS OF IN VITRO GLUCURONIDATION 57 2.3.4.1
DETERMINATION OF K M , V^,, ANDCL IM * 57 2.3.4.2 INFLUENCE OF ML3000 ON
THE GLUCURONIDATION OF ML3000-M2 61 2.3.5 BIOTRANSFORMATION IN PRIMARY
HUMAN HEPATOCYTES 64 2.3.5.1 BIOTRANSFORMATION OF ML3000 64 2.3.5.2
BIOTRANSFORMATION OF ML3247 67 2.3.5.3 BIOTRANSFORMATION OF DICLOFENAC
68 2.3.6 COUPLED OXIDATIVE-CONJUGATIVE METABOLISM IN DIFFERENT
MICROSOMES 71 2.3.6.1 IN VITRO METABOLISM OF ML3000 72 2.3.6.2 IN VITRO
METABOLISM OF ML3247 *-' 2.3.6.3 IN VITRO METABOLISM OF DICLOFENAC ^
2.3.7 IDENTIFICATION OF ENZYMES INVOLVED IN THE METABOLISM OF ML3000 89
2.3.7.1 IDENTIFICATION OF CYTOEHROME P450 ISOFORMS 90 2.3.7.2
IDENTIFICATION OF UDP- GLNCURONOSVLTRANSFERASE ISOFORMS '' 2.3.7.3
IDENTIFICATION OF CYTOEHROME P450 ISOFORMS INVOLVED IN THE OXIDATION OF
ML3000-M1 92 2.3.8 INHIBITION OF THE SEQUENTIAL OXIDATIVE METABOLISM '-
2.3.8.1 INFLUENCE OF MONTELUKAST ON ML3000 AND ML3247 METABOLISM 92
2.3.8.2 IMPACT OF ML3000-MI ON CYP2C8-ACTIVITY 94 2.3.8.3 INFLUENCE OF
MONTELUKAST ON DICLOFENAC METABOLISM 95 2.3.9 DETERMINATION OF ML3OOO-M2
ENANTIOMER RATIOS 97 2.4 DISCUSSION 10 3 PHARMACOKINETICS AND
DISPOSITION OF LICOFELONE-PRODRUGS 111 3.1 BACKGROUND AND OBJECTIVES ILL
3.2 MATERIALS AND METHODS 115 3.2.1 TEST ARTICLES AND REFERENCE
COMPOUNDS 115 3.2.2 CHEMICALS 116 3.2.3 APPARATUS 117 3.2.4 INSTRUMENTS
118 3.2.5 PREPARATION OF BUFFERS AND REAGENTS 118 3.2.6 PHARMACOKINETICS
OF ML3599, ML3600, AND ML3601 IN DOGS 120 3.2.6.1 ALLOCATION OF ANIMALS
120 3.2.6.2 BLOOD SAMPLING AND PREPARATION OF PLASMA SAMPLES 120 3.2.6.3
DETERMINATION OFMLSOOO, ML3599, ML3600 ANA" ML3601 BY LC-MS/MS AFTER
LIQUID-LIQUID EXTRACTION 121 3.2.7 INVESTIGATION OF TINE IN VITRO
STABILITY OF ML3599 AND ML3600 124 3.2.7.1 IN VITRO INCUBATIONS 124
3.2.7.2 ANALYSIS OF INCUBATION SAMPLES 125 3.2.8 PHARMACOKINETICS OF
CSY3100 AND CSY3104 IN RODENTS 126 3.2.8.1 ALLOCATION OF ANIMALS AND
SAMPLING 126 3.2.8.2 DETERMINATION OFCSY3100. CSY3104 AND ML3000 WITH
LC-MS/MS AFTER LIQUID-LIQUID EXTRACTION 127 3.2.9 IN VITRO METABOLISM OF
CSY3100 AND CSY3104 129 3.2.9.1 IN VITRO METABOLISM EXPERIMENTS 129
3.2.9.2 HPLC'UV ANALYSIS OF IN VITRO METABOLISM SAMPLES 130 3.2.10
VALIDATION OF THE ANALYTICAL METHODS 130 3.2.10.1 ANALYSIS OF
CALIBRATION STANDARDS 130 3.2 10.2 SPECIFICITY OF THE ANALYTICAL METHODS
131 3.2.10.3 ANALYTICAL QUALITY CONTROL 131 3.2.10.4 INTERNAL STANDARDS
132 3.2.11 DATA ANALYSIS 132 3.3 RESULTS 133 3 3 1 PHARMACOKINETICS OF
ML3599. ML360OAND ML3601 IN DOGS 133 3.3.2 STABILITY OF ML3599 AND
ML36OO M VITRO 137 3.3.3 PHARMACOKINETICS OF ML3000 MACROLIDC CONJUGATES
13S 3 3.3.1 TREATMENT OF COLLAGEN-INDUCED ARTHRITIS IN MITE WITH CSY3KKI
AND CSY3I04 IN COMPARISON WITH ML.3000 138 3.3.3.2 SUB-ACUTE TOXICITY
OFCSY.I 100 AND CSY3104 IN MUE 139 3.3.3.3 PHARMACOKINETICS OF CSY3I0O
AND CSY3IO4 IN RATS 139 3.3.4 METABOLISM OF CSY3100 AND CSY3104 143 3.4
DISCUSSION 146 4 SUMMARY 149 5 ZUSAMMENFASSUNG 151 6 REFERENCES 153 7
ADDENDUM 165 7.1 CALIBRATION DATA 165 7.2 TABULATED RESULTS OF QC SAMPLE
ANALYSIS 166 7.3 RESULTS OF THE PLASMA ANALYSIS OF ML3000-M4 168 7.4
LINEWEAVER-BURK PLOTS OF GLUCURONIDATION EXPERIMENTS 171 7.5 TABULATED
RESULTS OF IN VITRO METABOLISM EXPERIMENTS 175 7.6 CHROMATOGRAMS AND
TABULATED RESULTS OF THE DETERMINATION OF ENANTIOMER RATIOS 181 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Unger, Anke |
| author_facet | Unger, Anke |
| author_role | aut |
| author_sort | Unger, Anke |
| author_variant | a u au |
| building | Verbundindex |
| bvnumber | BV022506165 |
| ctrlnum | (OCoLC)254333337 (DE-599)BSZ263945944 |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01221nam a2200301 c 4500</leader><controlfield tag="001">BV022506165</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">070711s2007 d||| m||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)254333337</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BSZ263945944</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29T</subfield><subfield code="a">DE-188</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">15,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Unger, Anke</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Metabolism of Licofelone (ML3000)</subfield><subfield code="b">an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat</subfield><subfield code="c">von Anke Unger</subfield></datafield><datafield tag="246" ind1="1" ind2="1"><subfield code="a">Metabolismus von Licofelone (ML3000)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">VI, 184 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="a">Tübingen, Univ., Diss., 2007</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015713153&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015713153</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV022506165 |
| illustrated | Illustrated |
| index_date | 2024-07-02T17:57:35Z |
| indexdate | 2024-07-09T20:59:05Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015713153 |
| oclc_num | 254333337 |
| open_access_boolean | |
| owner | DE-29T DE-188 |
| owner_facet | DE-29T DE-188 |
| physical | VI, 184 S. graph. Darst. |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| record_format | marc |
| spelling | Unger, Anke Verfasser aut Metabolism of Licofelone (ML3000) an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat von Anke Unger Metabolismus von Licofelone (ML3000) 2007 VI, 184 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Tübingen, Univ., Diss., 2007 (DE-588)4113937-9 Hochschulschrift gnd-content GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015713153&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Unger, Anke Metabolism of Licofelone (ML3000) an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat |
| subject_GND | (DE-588)4113937-9 |
| title | Metabolism of Licofelone (ML3000) an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat |
| title_alt | Metabolismus von Licofelone (ML3000) |
| title_auth | Metabolism of Licofelone (ML3000) an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat |
| title_exact_search | Metabolism of Licofelone (ML3000) an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat |
| title_exact_search_txtP | Metabolism of Licofelone (ML3000) an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat |
| title_full | Metabolism of Licofelone (ML3000) an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat von Anke Unger |
| title_fullStr | Metabolism of Licofelone (ML3000) an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat von Anke Unger |
| title_full_unstemmed | Metabolism of Licofelone (ML3000) an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat von Anke Unger |
| title_short | Metabolism of Licofelone (ML3000) |
| title_sort | metabolism of licofelone ml3000 an anti inflammatory pyrrolizine acetic acid derivative metabolismus von licofelone ml3000 ein entzundungshemmendes pyrrolizinessigsaure derivat |
| title_sub | an anti-inflammatory pyrrolizine acetic acid derivative = Metabolismus von Licofelone (ML3000) : ein entzündungshemmendes Pyrrolizinessigsäure-Derivat |
| topic_facet | Hochschulschrift |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015713153&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT ungeranke metabolismoflicofeloneml3000anantiinflammatorypyrrolizineaceticacidderivativemetabolismusvonlicofeloneml3000einentzundungshemmendespyrrolizinessigsaurederivat AT ungeranke metabolismusvonlicofeloneml3000 |